[Current insights into the role of HIF-PHD axis in renal anemia].

Related Articles

[Current insights into the role of HIF-PHD axis in renal anemia].

Sheng Li Xue Bao. 2018 Dec 25;70(6):623-629

Authors: Cao JY, Liu BC

Abstract
Renal anemia, mainly caused by the deficiencies of erythropoietin (EPO) and iron metabolism disorder, is one of the most common complications of chronic kidney disease. Hypoxia-inducible factor (HIF) is a class of transcription factors responsible for maintaining homeostasis during oxygen deprivation. In normoxia, HIF is degraded by prolyl hydroxylase (PHD). While under hypoxic conditions, the hydroxylation activity of PHD is inhibited, and the cellular concentration of HIF is elevated, resulting in an increase in endogenous EPO production and iron absorption. Therefore, this regulating pathway, also termed as the HIF-PHD axis, has become a promising therapeutic target of treating renal anemia. Several innovative drugs acting as selective HIF-PHD inhibitors have been successfully developed in the past years, and some of them are undergoing clinical trials. In this review, we will introduce the definition and regulatory mechanism of HIF-PHD axis, as well as current insights into its physiologic and therapeutic role in renal anemia.

PMID: 30560271 [PubMed - in process]

from A via a.sfakia on Inoreader https://ift.tt/2EGacdE